Water-soluble granule intermediates for swine and poultry drinking-water medication impose a narrow processing window on residual moisture, particle size, and ionic buffering. Dihydrostreptomycin sulphate is freely soluble in water and practically insoluble in absolute ethanol, which excludes conventional aqueous wet granulation as the starting formulation route. In dry granulation via roller compaction at roll pressure 8–12 kN/cm, the API is blended with anhydrous lactose or dextrose monohydrate at 65–80% w/w, sodium citrate dihydrate at 1.5–3.0% w/w, and povidone K30 at 2–4% w/w. The ribbon compact is milled to granules with a target D90 of 355–500 µm; granule flow through automatic proportioning pumps is measured by bulk density 0.55–0.75 g/mL. A final loss-on-drying of ≤1.0% measured by USP <731> is required because moisture above 1.5% causes API migration to granule surfaces during storage and loss of content uniformity in 1 kg sachets. Dissolution of a 10 g granule dose in water at 20 °C is specified as complete within 60 s; hard water at 300 ppm calcium carbonate equivalent does not alter dissolution time when citrate buffer is present. The solution pH is maintained at 5.5–6.5, which avoids the yellow discoloration observed above pH 7.0 under accelerated storage at 40 °C/75% RH. The oral form is intended for local activity in the gut; systemic absorption from the gastrointestinal tract is minimal, so the granule must be distributed uniformly in drinking water over 3–5 days at product-specific doses. Particle size of the API component is controlled by jet milling to a D90 of ≤180 µm before dry granulation, because larger crystals segregate during high-speed filling.

What Limits Reconstitution Stability in Injectable Dihydrostreptomycin Sulphate for Multi-Dose Vials?

Reconstitution stability of injectable dihydrostreptomycin sulphate is governed by three interdependent variables: aqueous solution pH, headspace oxygen, and the presence of beta-lactam counter-ions. The sulphate salt is dissolved in Water for Injections at 200–250 mg/mL and buffered with anhydrous citric acid and sodium citrate dihydrate to a pH of 5.5–7.0. Below pH 5.0 the guanidino groups undergo acid-catalysed hydrolysis; above pH 7.5 the sulfate salt can generate the free base and precipitate in vials stored below 15 °C. Terminal moist-heat sterilisation at 121 °C for 15 min is generally avoided for aqueous concentrates because pH-dependent potency loss can exceed 5% and degradation products may fail the related substances limit of USP <621> chromatographic purity methods. Aseptic filtration through a 0.22 µm polyvinylidene fluoride or polyethersulfone membrane is used after bulk dissolution and carbon treatment. The sterile filtrate is filled under nitrogen into Type I glass vials with chlorobutyl stoppers; residual oxygen in the headspace is held below 2% v/v. For multi-dose vials, a preservative such as phenol 0.25–0.5% w/v or benzyl alcohol 1.0–2.0% w/v may be included, but compatibility with dihydrostreptomycin sulfate must be confirmed because phenolic preservatives can form insoluble complexes at near-neutral pH. Endotoxin control follows USP <85> with a lot limit of ≤0.25 EU/mg for parenteral veterinary products, and particulate matter must meet USP <788> large-volume injection limits if the labelled dose is diluted into intravenous fluids. Combination products containing penicillin G procaine are manufactured as a two-phase sterile suspension rather than as a single aqueous solution; aminoglycoside and beta-lactam actives interact in aqueous solution over several hours at room temperature, reducing potency of both components.

Dry cow intramammary formulations require a shear-thinning vehicle that retains dihydrostreptomycin sulphate in a homogeneous suspension throughout the 21-day dry period. The API is micronised to a D90 of ≤20 µm or D99 of ≤50 µm to avoid blocking the teat canal and to permit gradual release of drug from the intramammary depot. The vehicle is commonly a non-aqueous gel or oil-based suspension containing 3–5% w/w aluminium stearate in peanut oil or fractionated mineral oil; the viscosity at 10 s⁻¹ is adjusted to 2–6 Pa·s to allow syringeability through a short polyethylene cannula. Dihydrostreptomycin sulphate is practically insoluble in these vehicles, so sedimentation rate is controlled by particle size and yield stress rather than by surface charge. Syringe force is measured at 5 mm/s and is normally specified at ≤40 N; higher forces are associated with clinical misapplication and incomplete dose delivery. The combination with penicillin G procaine in dry cow syringes places additional constraints on water activity because the beta-lactam degrades above 0.6 aw, while dihydrostreptomycin sulfate itself is hydrolytically unstable in aqueous regions above 0.8 aw. Published forced-degradation data for this specific non-aqueous configuration are limited; the critical quality attributes are therefore derived from sedimentation screening and real-time stability batches rather than from a single validated kinetics model.

Sterile filling of intramammary ointments requires jacketed vessels at 40–50 °C and continuous recirculation to prevent particle sedimentation before volumetric piston filling. The filled syringes are leak-tested by vacuum decay at −0.6 bar and then released according to sterility Ph. Eur. 2.6.1, endotoxin Ph. Eur. 2.6.14, and content uniformity of both actives using HPLC. Batch records include a worst-case filling-line stop of 30 min, after which the first 20 mL of suspension is discarded to remove settled material. The final product is stored below 25 °C and protected from light; freeze-thaw cycling is not permitted because vehicle crystallisation can cause irreversible aggregation of the micronised dihydrostreptomycin sulfate and a sharp increase in syringe force.

When Milk Replacer Powders Carry Dihydrostreptomycin Sulphate Through Long Storage and Ambient Humidity

Milk replacer powders containing dihydrostreptomycin sulphate are manufactured as a dry blend rather than as a granule, because the end-use reconstitution in warm milk at 38–42 °C supplies sufficient agitation for complete dissolution. The blend is composed of the API, spray-dried skim milk powder or whey protein concentrate as a carrier, dextrose monohydrate, and sodium citrate dihydrate. Since dihydrostreptomycin sulphate is hygroscopic, the critical relative humidity of the blend is approximately 55–60%; packaging in aluminium foil laminate with desiccant sachets is required to keep moisture below 3.0% for a 24-month shelf life. Above 3.5% moisture, lactose in the milk replacer undergoes Maillard browning, and the resulting pH shift above 7.0 accelerates degradation of the aminoglycoside. Mixing is performed in a ribbon blender at 70–80% load volume for 15–20 min, but the API is pre-blended with 5–10% dextrose in a high-shear mixer for 3 min to break up agglomerates before addition to the main blender. Content uniformity is tested on 10 stratified samples; acceptance follows USP <905> for powder blends where the dose is filled into sachets. The reconstituted milk solution has a pH of 6.4–6.8; at this pH dihydrostreptomycin sulfate remains chemically stable for 2 h at room temperature, after which bacterial spoilage of the milk matrix rather than API degradation becomes the limiting factor. Because oral absorption is minimal, the milk replacer dose is retained in the intestinal lumen and must be administered before feeding when the abomasal emptying rate is highest. The product is not appropriate for systemic therapy; local activity against Gram-negative enteropathogens in the gut is the sole pharmacological target.

Immediate-Release Tablet and Capsule Compression Physics Under Tropical Humidity

Direct compression of dihydrostreptomycin sulphate tablets requires pre-drying of the API and the filler blend below 2.0% loss on drying before compression. The hygroscopic API raises equilibrium moisture content to 3.5% at 60% RH; moisture above this threshold causes punch filming and weight variation drift on rotary presses at 60–80 rpm. For a 50 mg tablet, a direct-compression matrix of microcrystalline cellulose (30–45% w/w), anhydrous lactose (40–55% w/w), crospovidone (3–5% w/w), colloidal silicon dioxide (0.5–1.0% w/w), and magnesium stearate (0.75–1.25% w/w) yields tablet hardness at 6–9 kp and friability below 0.8%. Lubrication is restricted to 2 min blending because longer magnesium stearate exposure produces hydrophobic films that delay disintegration to 12–15 min. Dissolution testing by USP <711> paddle at 50 rpm in 900 mL purified water commonly shows Q ≥80% in 15 min for optimised batches; the test remains discriminating for capsule segregation because the high aqueous solubility of dihydrostreptomycin sulphate masks content nonuniformity if the sample reaches the vessel before full disintegration. Capsule filling on a dosator machine requires granulation or slugging because the needle-like API crystals have poor flow; a roller-compacted granule with D90 of 250 µm and Carr index below 25 prevents capsule fill weight variation above 3% RSD. Compatibility with enteric coating is not required for local gastrointestinal activity, and any delayed-release coating would reduce local contact time in the jejunum and ileum.

Particle Size Reduction and Sterile Filtration Are Not Interchangeable for Parenteral Dihydrostreptomycin Sulphate

Particle size reduction and sterile filtration control different failure modes in parenteral dihydrostreptomycin sulphate manufacture and cannot be substituted for one another. Micronisation of the API to a D90 of ≤10 µm improves the reconstitution rate of a sterile powder cake, but the milling step itself can introduce amorphous regions that increase moisture uptake and reduce chemical stability. Sterile filtration of the compounded aqueous solution does not remove dissolved endotoxin or soluble degradation products; therefore the API lot must meet a bacterial endotoxin limit of USP <85> before filtration, and the solution must be sampled for related substances by USP <621> after 0.22 µm filtration. The use of terminal dry-heat sterilisation at 160 °C is contraindicated because dihydrostreptomycin sulfate begins to discolour and lose potency above 60 °C at low moisture; aseptic crystallisation from sterile-filtered solutions is the preferred route for sterile powder. On a filling line, the powder is filled by vacuum-assisted auger or dosing screw into pre-sterilised vials at 18–22 °C and 20–30% RH; higher relative humidity causes caking on the filling nozzle and intermittent fill weight drift above 2% RSD. After lyophilisation or aseptic crystallisation, the powder cake should reconstitute in Water for Injections within 30 s with gentle swirling; a reconstitution time above 120 s at 20 °C indicates surface collapse or amorphous content. The filled vials are checked for container closure integrity by dye ingress or vacuum decay, and particulate matter is controlled to USP <788> limits for injections. For combination powders with penicillin G procaine, the two actives are not micronised together because the shear input during milling accelerates the formation of an inactive amide complex; they are filled as separate sterile fractions into the same vial.